11d10
mAbexperimental
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2001 (NCT00033748)
Timeline
2000s
- Jan 1, 2001
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- LactadherinINHIBITOR
MFGE8 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- 11d10
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00045617 | Phase 2 | Jan 1, 2003 | National Cancer Institute (NCI), Southwest Oncology Group, University of Cincinnati |
| NCT00033748 | Phase 2 | Dec 1, 2001 | National Cancer Institute (NCI), University of Chicago |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 2 | 1 | 1 | 2001 |
| Southwest Oncology Group | Academic/Hospital | 1 | 1 | 1 | 2003 |
| University of Chicago | Academic/Hospital | 1 | 0 | 1 | 2001 |
| University of Cincinnati | Academic/Hospital | 1 | 0 | 1 | 2003 |
4 organizations
Page 1 / 1